FAMAR Group, a leading European pharmaceutical Contract Development and Manufacturing Organization (CDMO), has signed a contract manufacturing ...

ATHENS, Greece, Sept. 29, 2025 /PRNewswire/ -- After 16 years with FAMAR, including the last 4 years as CEO, Konstantinos Rengis decided to step down from his role for personal reasons, effective ...

Famar, a portfolio company of the private equity firm of MidEuropa, is set to acquire a sterile manufacturing facility in Homburg, Germany, from MiP Pharma as part of the Greek CDMO’s plan to expand ...

Active Biotech AB (publ) (NASDAQ STOCKHOLM: ACTI) today announced it has reached a manufacturing agreement with Famar Health Care Services Madrid SAU (“Famar”), a European provider of pharmaceutical ...

MidEuropa has agreed to acquire a majority stake in Famar, a pharmaceutical contract development and manufacturing organisation (CDMO), from ECM Partners and Metric Capital Partners (MCP).

MidEuropa aims to rebuild Famar’s North American presence and gain a footprint in Central Europe to turn the business into a highly desirable consolidation target, Matthew Strassberg, partner and head ...

HOMBURG, Germany, May 14, 2025 /PRNewswire/ -- FAMAR Group, a leading European pharmaceutical CDMO, is pleased to announce the signature of an agreement to acquire a sterile production site in Homburg ...

French CDMO Delpharm, which already has a dozen sites across Europe, is planning a big expansion with a deal to pick up five more, including one in North America, along with 1,300 employees in a deal ...

The pharmaceutical services firms Famar and Delpharm confirm that they are in talks about the sale of five Famar finished-drug manufacturing plants to Delpharm. The sites—three in France, one in the ...